bullish
Opthea Ltd (OPT AU): Lead Asset for Highly Prevalent Retinal Disease Moving Toward Commercialization
220 Views04 Aug 2022 19:11
SUMMARY
- Opthea Ltd (OPT AU) is developing OPT-302, a first-in-class investigational drug. With improved efficacy, OPT-302 has the potential to be the next transformative step in the treatment of wet AMD.
- Pivotal phase 3 trials are ongoing for OPT-302, with topline data expected in mid-2024. OTP-302 is expected to be launched in 2025. OPT-302 represents a multi-billion-dollar peak sales opportunity.
- As of December 2021, Opthea had cash balance of A$88 million and no debt. Over the trailing 12 months, the company had cash burn of A$56 million.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Opthea (OPT AU): Kicks Off A$80M Capital Raise To Support Phase 3 Trial of Lead Drug Candidate25 Aug 2023
- Opthea Ltd (OPT AU): Secured Funds as Lead Eye Drug Candidate Advancing in Phase 3 Trials28 Nov 2022
- Opthea Ltd (OPT AU): Lead Asset for Highly Prevalent Retinal Disease Moving Toward Commercialization04 Aug 2022
x